Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof
    3.
    发明申请
    Antigen Binding Molecules that Bind EGFR, Vectors Encoding Same, and Uses Thereof 有权
    绑定EGFR的抗原结合分子,编码相同的载体及其用途

    公开(公告)号:US20100233080A1

    公开(公告)日:2010-09-16

    申请号:US12724386

    申请日:2010-03-15

    摘要: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译: 本发明涉及抗原结合分子(ABM)。 在具体实施方案中,本发明涉及重组单克隆抗体,包括对人EGFR特异的嵌合,灵长类或人源化抗体。 此外,本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外,本发明涉及具有改善的治疗性质的具有改性糖基化的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。

    Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof
    5.
    发明授权
    Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof 有权
    癌胚抗原(CEA)抗体,其制备方法及其应用

    公开(公告)号:US09068008B2

    公开(公告)日:2015-06-30

    申请号:US12872908

    申请日:2010-08-31

    IPC分类号: C07K16/30 C07K16/46

    摘要: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies or variants thereof specific for cell surface or membrane bound human CEA. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译: 本发明涉及抗原结合分子(ABM)。 在具体实施方案中,本发明涉及重组单克隆抗体,包括特异于细胞表面或膜结合人CEA的嵌合,灵长类或人源化抗体或其变体。 此外,本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外,本发明涉及具有改善的治疗性质的具有改性糖基化的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。

    ANTIGEN BINDING MOLECULES THAT BIND EGFR, VECTORS ENCODING SAME, AND USES THEREOF
    8.
    发明申请
    ANTIGEN BINDING MOLECULES THAT BIND EGFR, VECTORS ENCODING SAME, AND USES THEREOF 有权
    抗体结合分子EGFR,载体编码它们及其用途

    公开(公告)号:US20120178106A1

    公开(公告)日:2012-07-12

    申请号:US13315989

    申请日:2011-12-09

    IPC分类号: G01N33/566 G01N33/53

    摘要: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

    摘要翻译: 本发明涉及抗原结合分子(ABM)。 在具体实施方案中,本发明涉及重组单克隆抗体,包括对人EGFR特异的嵌合,灵长类或人源化抗体。 此外,本发明涉及编码这种ABM的核酸分子以及包含该核酸分子的载体和宿主细胞。 本发明还涉及生产本发明的ABM的方法以及使用这些ABM在治疗疾病中的方法。 此外,本发明涉及具有改善的治疗性质的具有改性糖基化的ABM,包括具有增加的Fc受体结合和增加的效应子功能的抗体。